Metformin and breast cancer risk: a meta-analysis and critical literature review

被引:158
|
作者
Col, Nananda F. [1 ,2 ]
Ochs, Leslie [2 ]
Springmann, Vicky [3 ]
Aragaki, Aaron K. [4 ]
Chlebowski, Rowan T. [5 ]
机构
[1] Shared Decis Making Resources, Georgetown, ME 04548 USA
[2] Univ New England, Coll Osteopath Med, Biddeford, ME USA
[3] Univ Montreal, Montreal, PQ, Canada
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[5] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA
关键词
Metformin; Breast cancer; Meta-analyses; Literature review; DIABETES-MELLITUS; INCIDENT CANCER; MANAGEMENT; OUTCOMES; COHORT; DRUGS; WOMEN;
D O I
10.1007/s10549-012-2170-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Observational studies have suggested that metformin decreases the incidence of several common cancers. However, findings regarding breast cancer have been mixed. In order to explore this issue, a systematic literature review and meta-analysis were performed with a focus on potential biases. We conducted a comprehensive literature search for all pertinent studies addressing metformin use and breast cancer risk by searching PubMed, Cochrane Library, and Scopus (which includes Embase, ISI Web of Science) using the Mesh terms: "metformin" or "biguanides" or "diabetes mellitus, type 2/therapy" and "cancer" or "neoplasms." When multiple hazard ratios (HR) or odds ratio (OR) were reported, the most adjusted estimate was used in the base-case analysis. We pooled the adjusted HR and performed sensitivity analyses on duration of metformin use (> or a parts per thousand currency sign3 years use), study quality (assessed using the GRADE system), and initial observation year of the cohort (before vs after 1997). From a total of 443 citations, 18 full-text articles were considered, and seven independent studies were included. All were observational (four cohort and three case control). Our combined OR of all seven studies was 0.83 (0.71-0.97). Stronger associations were found when analyses were limited to studies estimating the impact of longer metformin use (OR = 0.75. 95 % CI 0.62, 0.91) or among studies that began observing their cohort before 1997 (OR = 0.68. 95 % CI 0.55-0.084). Stratification according to study quality did not affect the combined OR but higher quality studies had smaller CI and achieved statistical significance. Interpretation is limited by the observational nature of reports and different comparison groups. Our analyses support a protective effect of metformin on breast cancer risk among postmenopausal women with diabetes. Clinical trials are needed for definitive determination of the role of metformin in breast cancer risk reduction.
引用
收藏
页码:639 / 646
页数:8
相关论文
共 50 条
  • [31] Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis
    Danxia Chu
    Jie Wu
    Kaili Wang
    Mengling Zhao
    Chunfang Wang
    Liuxia Li
    Ruixia Guo
    BMC Cancer, 18
  • [32] Is metformin use associated with a reduced risk of oesophageal cancer? A systematic review and meta-analysis
    Chen, Yue
    Cheng, Xingyu
    Sun, Chenyu
    Kim, Na Hyun
    Kailas, Sujatha
    Qureshi, Faisal
    Karadsheh, Zeid
    Wu, Yile
    Hu, Lei
    Zhou, Zhen
    Bhan, Chandur
    Kim, Keun Young
    Manem, Raveena
    Cheng, Ce
    Zhou, Qin
    POSTGRADUATE MEDICAL JOURNAL, 2022, 98 (1165) : 866 - 870
  • [33] Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis
    Chu, Danxia
    Wu, Jie
    Wang, Kaili
    Zhao, Mengling
    Wang, Chunfang
    Li, Liuxia
    Guo, Ruixia
    BMC CANCER, 2018, 18
  • [34] Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta-analysis
    Mesquita, Leonardo A.
    Spiazzi, Bernardo F.
    Piccoli, Giovana F.
    Nogara, Daniela A.
    da Natividade, Gabriella R.
    Garbin, Henrique I.
    Wayerbacher, Laura F.
    Wiercinski, Vanessa M.
    Baggio, Viviane A.
    Zingano, Carolina P.
    Schwartsmann, Gilberto
    Lopes, Gilberto
    Petrie, John R.
    Colpani, Veronica
    Gerchman, Fernando
    DIABETES OBESITY & METABOLISM, 2024, 26 (05): : 1929 - 1940
  • [35] Family history and the risk of breast cancer: A systematic review and meta-analysis
    Pharoah, PDP
    Day, NE
    Duffy, S
    Easton, DF
    Ponder, BAJ
    INTERNATIONAL JOURNAL OF CANCER, 1997, 71 (05) : 800 - 809
  • [36] Folate intake and the risk of breast cancer: a systematic review and meta-analysis
    Tio, Martin
    Andrici, Juliana
    Eslick, Guy D.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (02) : 513 - 524
  • [37] A systematic review and meta-analysis on tubal ligation and breast cancer risk
    Najdi, Nazila
    Esmailzadeh, Arezoo
    Shokrpour, Maryam
    Nikfar, Somayeh
    Razavi, Seyedeh Zahra
    Sepidarkish, Mahdi
    Maroufizadeh, Saman
    Safiri, Saeid
    Almasi-Hashiani, Amir
    SYSTEMATIC REVIEWS, 2022, 11 (01)
  • [38] Estradiol therapy and breast cancer risk: a systematic review and meta-analysis
    Yang, Zhilan
    Hu, Ying
    Xu, Liangzhi
    Kang, Deying
    GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 : 77 - 78
  • [39] Breast cancer risk factors in Iran: a systematic review & meta-analysis
    Shamshirian, Amir
    Heydari, Keyvan
    Shams, Zahra
    Aref, Amir Reza
    Shamshirian, Danial
    Tamtaji, Omid Reza
    Asemi, Zatollah
    Shojaie, Layla
    Mirzaei, Hamed
    Mohammadi, Neda
    Zibaee, Behdad
    Karimifar, Keyvan
    Zarandi, Bahman
    Hedayatizadeh-Omran, Akbar
    Alizadeh-Navaei, Reza
    HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION, 2020, 41 (04)
  • [40] A systematic review and meta-analysis on tubal ligation and breast cancer risk
    Nazila Najdi
    Arezoo Esmailzadeh
    Maryam Shokrpour
    Somayeh Nikfar
    Seyedeh Zahra Razavi
    Mahdi Sepidarkish
    Saman Maroufizadeh
    Saeid Safiri
    Amir Almasi-Hashiani
    Systematic Reviews, 11